Effectiveness of Sugammadex on Muscle Relaxant Reversal in Preterm Neonates
NCT ID: NCT04566796
Last Updated: 2020-09-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
60 participants
INTERVENTIONAL
2020-08-11
2021-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The secondary aim is to evaluate the safety of using Sugammadex in preterm neonates and to detect any complications that may occur in this age group.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sugammadex Given for the Reversal of Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants
NCT02708056
Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)
NCT03909165
Sugammadex Dose Finding Under Two Years Old
NCT06575036
Electromyographic Activity of the Respiratory Muscles During Neostigmine or Sugammadex Enhanced Recovery After Neuromuscular Blockade
NCT02403063
Pharmacokinetic-pharmacodynamic Analysis of Sugammadex for Conventional Reversal in Children
NCT04347486
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
(Group N)
patients in this group will receive 0.02 mg/kg atropine with neostigmine 0.05 mg/kg IV. to reverse the action of the neuromuscular blocker given.
Neostigmine
give 0.02 mg/ kg atropine and 0.05 mg/kg neostigmine IV. as muscle reversal drug in premature infants
(Group S)
the patients will receive Sugammadex 2mg/kg IV. As the reversal agent
Sugammadex
give 2 mg/ kg as muscle reversal drug in premature infants
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sugammadex
give 2 mg/ kg as muscle reversal drug in premature infants
Neostigmine
give 0.02 mg/ kg atropine and 0.05 mg/kg neostigmine IV. as muscle reversal drug in premature infants
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* scheduled for elective inguinal hernia repair
Exclusion Criteria
* patient is with any diseases affecting the neuromuscular junction
* Patients with family history of malignant hyperthermia
28 Days
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alexandria University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yasser Mohamed Mohamed Osman
assistant professor of anesthesia Alexandria university
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ahmed M Elshafie
Role: PRINCIPAL_INVESTIGATOR
Alexandria University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alexandria university
Alexandria, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
234
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.